semaglutide pubchem SID 354702201 - PubChem
Description
doi: Raven LM, Brown C, Greenfield JR
Novo Nordisks once-daily oral Wegovy (25 mg semaglutide) is now approved for adults with obesity, or overweight patients with at least one weight-related condition, marking the first pill-based GLP-1 option indicated for both weight loss and cardiovascular risk reduction
While additional research is needed to fully understand the nexus between the drug and these adverse outcomes, these studies point to the substantial safety concerns that may have been overlooked by the manufacturer
PlexusDx providers monitor your symptoms weekly to ensure you're managing well and adjust your treatment plan as needed
PubMed Central, Hira, Tohru, et al
